Published Online
on January 5, 2006

A more recent version of this article appeared on February 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/2/456    most recent 01.STR.0000199845.27512.84v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ho, G. Y.-H. Articles by Chen, C. P.L.-H. Search for Related Content PubMed PubMed Citation Articles by Ho, G. Y.-H. Articles by Chen, C. P.L.-H. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Coronary Artery Disease Stroke Transient Ischemic Attack Hazardous Substances DB CYANOCOBALAMIN FOLIC ACID Related Collections Primary prevention Genetics of Stroke Related Article

Submitted on July 27, 2005
Revised on November 6, 2005
Accepted on November 15, 2005

Methylenetetrahydrofolate Reductase Polymorphisms and Homocysteine-Lowering Effect of Vitamin Therapy in Singaporean Stroke Patients

Grace Y.-H. Ho BSc (Hons); John W. Eikelboom FRCPA; Graeme J. Hankey FRACP; Chen-Ru Wong BSc; Siew-Li Tan BSc; Jesscia B.-C. Chan BSc; and Christopher P.L.-H. Chen FRCP^*

From the Department of Neurology (G.Y.-H.H., C.-R.W., S.-L.T.), Singapore General Hospital; Department of Medicine (J.W.E.), McMaster University, Hamilton, Canada; Stroke Unit (G.J.H.), Royal Perth Hospital, Australia; and Department of Neurology (J.B.-C.C., C.P.L.-H.), National Neuroscience Institute, Singapore General Hospital Campus.

^* To whom correspondence should be addressed. E-mail: gnrcc{at}sgh.com.sg.

Background and Purpose--Increased plasma total homocysteine (tHcy) levels are a risk factor for stroke and can be reduced with vitamin therapy. However, data on the tHcy-lowering effects of vitamins are limited largely to white gene polymorphism(s).

Methods--A total of 443 eligible patients were recruited after presenting with ischemic stroke within the past 7 months. Patients were randomized to receive either placebo or vitamins. Fasting blood samples collected at baseline and at 1 year were assayed for levels of plasma tHcy. Patients were genotyped for MTHFR C677T and A1298C polymorphisms.

Results--Mean baseline tHcy was similar in the 2 groups (placebo 13.7 µmol/L; vitamins 14.0 µmol/L; P=0.70). At 1 year, mean tHcy was 14.5 µmol/L in the placebo group compared with 10.7 µmol/L in the vitamin group (difference 3.8 µmol/L; 95% CI, 2.8 to 4.8 µmol/L; P<0.0001). MTHFR C677T genotype was an independent determinant of tHcy levels at baseline (P=0.005), but A1298C was not (P=0.08). Neither polymorphism significantly influenced the effect of vitamin therapy on tHcy at 1 year. The magnitude of the reduction in tHcy levels at 1 year with vitamin therapy was similar, irrespective of MTHFR genotypes.

Conclusions--Vitamin therapy reduces mean tHcy levels by 3.8 µmol/L in the Singaporean stroke population studied. MTHFR C677T but not A1298C is independently associated with tHcy levels at baseline, and neither impacts the tHcy-lowering effect of vitamins used in this study.

Key words: methylenetetrahydrofolate reductase • polymorphism • homocysteine • stroke

Related Article:

Homocysteine: Call Off the Funeral

J. David Spence
Stroke 2006 37: 282-283. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				K. Kasiman, J. W. Eikelboom, G. J. Hankey, S. P.-K. Lee, J. P.-Z. Lim, J. H.-Q. Lee, H.-M. Chang, M.-C. Wong, and C. P.L.-H. Chen Ethnicity Does Not Affect the Homocysteine-Lowering Effect of B-Vitamin Therapy in Singaporean Stroke Patients Stroke, June 1, 2009; 40(6): 2209 - 2211. [Abstract] [Full Text] [PDF]

				J. D. Spence Homocysteine: Call Off the Funeral Stroke, February 1, 2006; 37(2): 282 - 283. [Full Text] [PDF]